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Abstract
Introduction: Currently no evidence-based guideline exists for the approach to hypophosphatemia in critically ill
patients.
Methods: We performed a narrative review of the medical literature to identify the incidence, symptoms, and
treatment of hypophosphatemia in critically ill patients. Specifically, we searched for answers to the questions
whether correction of hypophosphatemia is associated with improved outcome, and whether a certain treatment
strategy is superior.
Results: Incidence: hypophosphatemia is frequently encountered in the intensive care unit; and critically ill patients
are at increased risk for developing hypophosphatemia due to the presence of multiple causal factors. Symptoms:
hypophosphatemia may lead to a multitude of symptoms, including cardiac and respiratory failure. Treatment:
hypophosphatemia is generally corrected when it is symptomatic or severe. However, although multiple studies
confirm the efficacy and safety of intravenous phosphate administration, it remains uncertain when and how to
correct hypophosphatemia. Outcome: in some studies, hypophosphatemia was associated with higher mortality; a
paucity of randomized controlled evidence exists for whether correction of hypophosphatemia improves the
outcome in critically ill patients.
Conclusions: Additional studies addressing the current approach to hypophosphatemia in critically ill patients are
required. Studies should focus on the association between hypophosphatemia and morbidity and/or mortality, as
well as the effect of correction of this electrolyte disorder.
Introduction
Electrolyte disorders frequently develop in critically ill
patients during course of stay in the intensive care unit
(ICU). Therefore, ICU patients are routinely monitored
for electrolyte disorders, and it is common practice to
correct them. Hypophosphatemia is one of those fre-
quently encountered electrolyte disorders, for which
many causative factors are present in critically ill
patients. It is uncertain when and how to correct hypo-
phosphatemia, and whether correction affects outcome
in critically ill patients.
We searched the literature on hypophosphatemia in ICU
patients to identify the incidence, symptoms, and treat-
ment of hypophosphatemia. We searched for answers to
the following questions: (a) whether correction of hypo-
phosphatemia is associated with improved outcome; and
(b) whether a certain treatment strategy is superior.
Materials and methods
The Medline database was searched to identify articles
from 1969 to 2010 containing the Medical Subjects
Heading (MeSH) term “hypophosphatemia.” We
included clinical studies and experimental trials, as well
as case reports. Results were limited to articles in the
English language and to articles on humans. This search
yielded 1,413 articles. The Cochrane Library was also
searched for current trials on hypophosphatemia, which
yielded no results. All articles were screened for rele-
vance to critically ill patients; these articles were studied
in detail. Notably, articles on chronic hypophosphatemia
(for example, hereditary hypophosphatemic syndromes)
were excluded.
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Phosphate metabolism and causes of hypophosphatemia
in critically ill patients
Phosphorus is an essential element for all living cells,
with different functions (Table 1) [1]. The phosphate
balance is a complex interplay between phosphate
uptake and phosphate excretion (Figure 1). Normal
values of the total serum phosphate level are 0.80 to
1.45 mmol/L (2.5 to 4.5 mg/dl).
Hypophosphatemia can be caused by three different
mechanisms [1,2]: decreased intestinal absorption,
increased renal excretion, or internal redistribution of
inorganic phosphate (Figure 1). In most patients with
severe hypophosphatemia, both depletion of total body
phosphorus stores and redistribution of phosphate to
the intracellular space are found. Decreased intestinal
absorption of phosphate rarely causes hypophosphate-
mia, as a low-phosphate diet increases renal reabsorp-
tion and enhances intestinal uptake of phosphate. Still,
malnutrition, diarrhea, and nasogastric suction are com-
mon features in critically ill patients.
Redistribution across the cell membrane is the most
common cause of hypophosphatemia in ICU patients
and can be caused by multiple clinical conditions [1,3]:
respiratory alkalosis-induced increase of intracellular pH
causes phosphate to enter the cell by stimulating glyco-
lysis [4]; administration of glucose and insulin also sti-
mulates carbohydrate metabolism, during which
phosphate is transported into the cells along with glu-
cose; high serum levels of catecholamines such as epi-
nephrine and norepinephrine, whether endogenous or
exogenous, cause a decrease in serum phosphate [5];
cellular uptake of phosphate is increased under certain
specific conditions such as the hungry-bone syndrome,
and diseases with rapid cell proliferation such as acute
leukemia; renal excretion of phosphate is increased by
metabolic acidosis, and by many drugs, including diure-
tics, glucocorticoids [6], aminoglycosides, antiretroviral
drugs, and anticancer drugs.
Serum phosphate levels are inversely correlated to
levels of the inflammatory cytokines interleukin-6 and
tumor necrosis factor-a [7]. The exact mechanism is
unclear: renal phosphate excretion is very low in
patients receiving interleukin therapy for cancer [8], sug-
gesting that high interleukin levels cause internal redis-
tribution of phosphate; hypophosphatemia may be
caused by increased phosphate utilization by immune
cells. Hypophosphatemia can be found in patients with
severe infections, such as sepsis. Especially patients with
Gram-negative bacteremia may develop hypophosphate-
mia [9]. Hypophosphatemia correlates to severity of ill-
ness and can even be used as a prognostic parameter in
sepsis patients [10]. Infection with Legionella species is
particularly associated with hypophosphatemia [11].
Hypophosphatemia often develops in the postoperative
phase [12-15]. Multiple causal factors may be present,
such as respiratory alkalosis, administration of insulin,
and the use of diuretics. This is particularly true for
major surgery, such as cardiac surgery and abdominal
aortic surgery. The role of cardiopulmonary bypass is
not clear. After major hepatic surgery, hypophosphate-
mia is extremely frequent. Reported mechanisms involve
both shifts of phosphate into hepatocytes [16] and renal
phosphate wasting [17]. Hypophosphatemia is reported
to be more frequently encountered in trauma patients
[18]. Renal phosphate handling is altered in trauma
patients, resulting in inadequately increased urinary
phosphate excretion. Hypophosphatemia is even more
frequent in burn-wound victims, where phosphate is
lost through the skin [19,20]. In patients with head
trauma, induction of polyuresis may be an aggravating
factor [21].
In patients with malnutrition, a so-called refeeding
syndrome may develop when they receive (par-)enteral
feeding, a syndrome characterized by multiple metabolic
abnormalities including depletion of total body phos-
phorus stores and redistribution of phosphate to the
intracellular compartment, which may result in severe
hypophosphatemia [22].
Hypothermia induces polyuresis and is associated with
hypophosphatemia as well [23]. The use of (continuous)
renal replacement therapy may lead to hypophosphatemia
when low-phosphate replacement solution and dialysate
are used. Patients who require high-flux dialysis for
Table 1 Functions of phosphate
Form Function
Hydroxyapatite Bone structure
Phospholipids Structure of cell membranes
Adenosine triphosphate (ATP) and creatine phosphate Energy storage and metabolism
Nucleic acids and nucleoproteins Genetic translation
Phosphorylation of proteins Key regulatory mechanism; activation of enzymes, cell-signaling cascade
2,3-Diphosphoglycerate Modulates oxygen release by hemoglobin
Inorganic phosphate Acid-base buffer
Geerse et al. Critical Care 2010, 14:R147
http://ccforum.com/content/14/4/R147
Page 2 of 8intoxications are especially at risk. Addition of potassium
phosphate to dialysate and replacement fluids safely pre-
vents the development of hypophosphatemia [24].
Finally, patients with diabetic ketoacidosis commonly
present with hypophosphatemia due to increased urinary
phosphate excretion. Phosphate levels generally decrease
further during treatment because of intracellular shifting
along with glucose and potassium [25].
Epidemiology of hypophosphatemia
Table 2 summarizes the reported incidence and preva-
lence of hypophosphatemia in surgical and medical ICU
patients [7,12,14,15,17-19,21,26-30]. Hypophosphatemia
is usually categorized as moderate (serum phosphate
l e v e lo f0 . 3 2t o0 . 6 5m m o l / L( 1t o2m g / d l )o rs e v e r e
(<0.32 mmol/L (<1 mg/dl)). In the general hospital popu-
lation, the prevalence of moderate hypophosphatemia
ranges between 2.2 and 3.1% [31,32], and the prevalence
of severe hypophosphatemia is reported to be 0.2 to 0.4%
[32-34]. One study reports that 45% of all hospital hypo-
phosphatemia cases occur in the ICU population [35].
Hypophosphatemia has a higher incidence in certain
patient groups, such as patients with diabetic ketoacido-
sis, sepsis, and postoperative patients. Hypophosphatemia
is found in as many as 34% of patients after elective
cardiac surgery [12]. An extremely high incidence of
hypophosphatemia is reported after major hepatic sur-
gery, where almost all patients develop hypophosphate-
mia in the first postoperative week [17,26]. In this group,
serum phosphate levels decrease to a nadir within
approximately 2 days and recover in the following days.
This early nadir is also described after cardiac surgery
and in patients with diabetic ketoacidosis and the refeed-
ing syndrome. Trauma patients have a higher incidence
of hypophosphatemia, especially patients with burn
wounds [19] and head trauma [21]. Although the use of
renal replacement therapy leads to hypophosphatemia,
no epidemiologic reports were found.
Correction of hypophosphatemia, when encountered,
is not reported in epidemiologic studies and the sponta-
neous course of serum phosphate levels without treat-
ment is generally not addressed.
Symptoms of hypophosphatemia
Serum phosphate levels do not accurately reflect total
body phosphorus stores; hence the degree of hypopho-
sphatemia does not always correlate to the presence of
symptoms. Although most patients with hypophospha-
temia do not develop symptoms, fatal complications
have been described. A common mechanism in
Figure 1 Phosphate metabolism and causes of hypophosphatemia.
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energy metabolism, leading to cellular dysfunction in
multiple organ systems. Symptoms are summarized in
Table 3.
Respiratory effects
Hypophosphatemia is associated with respiratory muscle
dysfunction, potentially resulting in (acute) respiratory
failure and weaning problems [36-38]. The mechanism
is considered to be decreased availability of phosphate-
containing energy sources. Depletion of 2,3- diphospho-
glycerate (2,3-DPG) shifts the oxygen dissociation curve
to the left, decreasing oxygen delivery to peripheral tis-
sue [39,40]. This might be especially relevant in patients
with chronic pulmonary disease, as these patients may
have higher 2,3-DPG levels to compensate for hypoxe-
mia. In addition, hypophosphatemia has also been asso-
ciated with decreased tissue oxygenation after correction
for 2,3-DPG levels [41].
Cardiovascular effects
Hypophosphatemia can lead to myocardial dysfunction
and arrhythmias. Phosphate depletion causes impaired
energy metabolism in the myocardium, leading to
decreased contractility [42,43]. Severe acute heart failure
has been described in several case reports in the pre-
sence of severe hypophosphatemia. Hypophosphatemia
after cardiac surgery was associated with higher require-
ments of inotropic support [12]. Correction of hypopho-
sphatemia is associated with improved cardiac output
[14]. Hypophosphatemia is a significant predictor of
ventricular tachycardia after myocardial infarction [44]
and a correlation with arrhythmias has been suggested
in septic patients [45]. During correction of hypopho-
sphatemia, phosphate may precipitate with calcium and
cause hypocalcemia. It is important to keep in mind
that hypocalcemia can negatively influence cardiac func-
tion as well.
Other effects
Hypophosphatemia can cause hematologic dysfunction
[46-48], insulin resistance [49], and a number of neuro-
muscular symptoms (Table 3). Of the latter, rhabdomyo-
lysis [50,51] and central pontine myelinolysis [52,53] are
most severe. Besides hypophosphatemia, critically ill
Table 2 Prevalence and/or incidence of hypophosphatemia
Author [ref.] Year Population/disease Number of patients Definition of hypophosphatemia Prevalence Incidence
Surgical ICU patients
Goldstein et al. [15] 1985 Thoracic surgery 34 <0.80 mmol/L - 56%
Cardiac surgery 40 <0.80 mmol/L - 50%
Zazzo et al. [14] 1995 Surgical ICU 208 <0.80 mmol/L - 28.8%
≤0.50 mmol/L - 17.3%
≤0.20 mmol/L - 2.4%
Buell et al. [26] 1998 Hepatic surgery 35 <0.80 mmol/L - 67%
Cohen et al. [12] 2004 Cardiac surgery 566 <0.48 mmol/L - 34.3%
Salem et al. [17] 2005 Hepatic surgery 20 <0.70 mmol/L - 100%
Medical ICU patients
Daily et al. [18] 1990 Trauma patients 12 <0.80 mmol/L - 75%
<0.50 mmol/L - 56%
Kruse et al. [27] 1992 General ICU patients 418 <0.80 mmol/L - 28%
Marik et al. [28] 1996 Refeeding after >48 h starvation 62 <0.65 mmol/L - 34%
<0.32 mmol/L - 6%
Berger et al. [19] 1997 Burn injuries 16 <0.80 mmol/L - 100%
<0.30 mmol/L - 50%
Barak et al. [7] 1998 Sepsis 99 <0.80 mmol/L 80% -
Infection without sepsis 32 <0.80 mmol/L 65% -
Sepsis, negative blood culture 37 <0.80 mmol/L 80% -
Sepsis, postive blood culture 30 <0.80 mmol/L 80% -
Polderman et al. [21] 2000 Head trauma 18 <0.60 mmol/L 61% -
Milionis et al. [29] 2002 Severe heart failure 86 <0.77 mmol/L 13% -
Dominguez-Roldan
et al. [30]
2005 Brain-dead patients 50 <0.80 mmol/L - 72%
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risk for neurologic alterations, and causality is not well
documented.
Hypophosphatemia and mortality
Multiple studies show an association between hypopho-
sphatemia and increased mortality [10,12,14,35,54-59].
Severe hypophosphatemia has been reported to predict
up to eightfold increased mortality rate in sepsis patients
[10]. However, hypophosphatemia has not been asso-
ciated with increased mortality after cardiac surgery [12]
and in diabetic ketoacidosis [54]. It remains unclear
whether hypophosphatemia actually contributes to mor-
tality, or merely is a marker for severity of illness.
Whether correction of hypophosphatemia reduces mor-
tality is currently unknown.
Correction of hypophosphatemia
With the high prevalence of hypophosphatemia in criti-
cally ill patients, as well as their susceptibility to life-
threatening symptoms, frequent laboratory monitoring
is recommended, especially in previously mentioned
high-risk groups. It is generally recommended to correct
hypophosphatemia in hypophosphatemic patients with
associated symptoms [2,60]. However, no randomized
controlled evidence indicates whether correction of
hypophosphatemia in apparently asymptomatic patients
leads to improved outcome. Taking this into account,
the indication for – and recommended frequency of –
laboratory monitoring and treatment remains debatable.
Correction of hypophosphatemia is possible via oral or
intravenous routes. Intravenous administration of phos-
phate is not without complications, though. Phosphate
may precipitate with calcium. Large intravenous doses
of phosphate may result in hyperphosphatemia, hypo-
magnesemia, hypocalcemia, and hypotension. It is there-
fore necessary to know when intravenous therapy is
indicated, and how much and how fast phosphate
should be supplied. Intravenous therapy is generally
recommended in symptomatic hypophosphatemia and
phosphate levels <0.32 mmol/L. Multiple studies have
evaluated the efficacy and safety of intravenous phos-
phate repletion regimens (Table 4) [61-67]. These stu-
dies generally agree that aggressive phosphate
supplementation is safe with phosphate doses up to
45 mmol with infusion rates up to 20 mmol per hour.
Hyperkalemia is prevented by using sodium phosphate
instead of potassium phosphate in patients with potas-
sium levels >4 mmol/L.
Moderate hypophosphatemia can be treated with oral
supplementation of phosphate. One should keep in
mind that active vitamin D is required for intestinal
absorption of phosphate. Typical oral supplementation
amounts are three times the normal daily intake, with
advised amounts of 2.5 to 3.5 g (80 to 110 mmol) per
day, divided over two to three doses. Patients who
receive feeding after a period of starvation are often
phosphate depleted, so additional phosphate should be
added to nutritional preparations. An additional preven-
tive strategy is to build up the caloric intake slowly [22].
The total required amount of phosphate cannot be pre-
dicted by serum phosphate levels, as phosphate shifts
between multiple body compartments.
Dipyridamole can decrease urinary phosphate loss
[68]. Further research is needed to establish further the
role of this drug in the treatment of hypophosphatemia
in critically ill patients.
Discussion
Critically ill patients have a high prevalence of hypopho-
sphatemia because of the presence of multiple causal
factors. Hypophosphatemia may lead to a multitude of
symptoms, but most often remains asymptomatic.
Hypophosphatemia, however, is associated with
increased mortality in important patient subgroups. It is
important to investigate whether hypophosphatemia
causes higher mortality in itself, or rather is associated
with a higher severity of illness.
Table 3 Symptoms of hypophosphatemia
Respiratory
Respiratory muscle dysfunction
Acute respiratory failure
Failure to wean from mechanical ventilation
Decreased peripheral oxygen delivery
Cardiovascular
Decreased myocardial contractility
Acute heart failure
Increased inotropic requirement
Arrhythmia
Ventricular tachycardia
Supraventricular tachycardia
Premature beats
Hematologic
Hemolysis
Leukocyte dysfunction
Endocrine
Insulin resistance
Neuromuscular
Skeletal muscle weakness
Rhabdomyolysis
Polyneuropathy
Altered mental status
Seizures
Encephalopathy
Central pontine myelinolysis
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phosphate levels are not routinely measured in all criti-
cally ill patients. The spontaneous course of serum
phosphate is not well documented in the literature, so it
is insufficiently clear whether an initially low phosphate
level after surgery will return to normal spontaneously.
Although multiple studies have evaluated the efficacy
and safety of phosphate repletion regimens, the effect
on mortality and morbidity is not well reported. Cur-
rently, no widely agreed-on guidelines exist concerning
the approach to hypophosphatemia in critically ill
patients, because evidence is lacking on when and how
to treat hypophosphatemia.
A reasonable approach awaiting randomized con-
trolled trial evidence would be to reserve intravenous
correction of hypophosphatemia for patients with asso-
ciated symptoms or phosphate levels <0.32 mmol/L.
Doses of up to 40 mmol of sodium phosphate, adminis-
tered at a speed of up to 20 mmol per hour, are proven
to be safe. Additional studies are required, addressing
the current approach to hypophosphatemia in critically
ill patients, as well as the association of hypophosphate-
mia with morbidity and mortality, and the effect of
treatment. Evidence-based guidelines are needed to
guide critical care physicians in the diagnosis and treat-
ment of hypophosphatemia.
Conclusions
Additional studies are required to address the current
approach to hypophosphatemia in critically ill patients,
as well as the association of hypophosphatemia with
morbidity and mortality, and the effect of the correction
of this electrolyte disorder.
Key messages
￿ Critically ill patients have a high prevalence of
hypophosphatemia because of the presence of multi-
ple causal factors.
￿ Hypophosphatemia may lead to a multitude of
symptoms, including cardiac and respiratory failure,
and is associated with higher mortality.
￿ Although multiple studies confirm the efficacy and
safety of intravenous phosphate administration, it is
unknown which treatment strategy is superior.
￿ Nevertheless, correction of hypophosphatemia has
not been shown to improve outcome.
Abbreviations
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